On
“Through the closing of the acquisition of TXP Pharma, we are now in position of a pipeline which in addition to our very promising lead candidate drug, AP1189, consists of an additional clinical candidate, TXP-11, and several pre-clinical assets that increases our attractiveness towards potential business partners”, said Jeppe Øvlesen, SynAct’s CEO.
“The TXP pipeline and first and foremost TXP-11 that we intend to prepare for clinical development during 2023 gives us a unique opportunity to pursue development of melanocortin agonists for organ protection in the critical care segment including major surgery. To promote resolution in this patient segment would be a very attractive treatment approach to reduce organ dysfunction, which is a major clinical challenge”, commented
For more information regarding the acquisition of TXP, please see the press release from
The information was submitted for publication, through the agency of the contact persons set out below, at 4.00 p.m CET on
© Modular Finance, source